Hand dermatitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hand dermatitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Alitretinoin and Ciclosporin for Patients with Moderate to Very Severe Hand Eczema https://clinicaltrials.eu/trial/study-comparing-alitretinoin-and-ciclosporin-for-patients-with-moderate-to-very-severe-hand-eczema/ Wed, 29 Apr 2026 14:58:03 +0000 https://clinicaltrials.eu/trial/study-comparing-alitretinoin-and-ciclosporin-for-patients-with-moderate-to-very-severe-hand-eczema/ This clinical trial is focused on studying the effectiveness of two medications, alitretinoin and cyclosporine, in treating patients with hand eczema. Hand eczema is a skin condition that causes redness, itching, and sometimes blisters on the hands. The purpose of the study is to compare how well these two medications work in improving the condition of patients with moderate to very severe hand eczema.

Participants in the study will be randomly assigned to receive either alitretinoin or cyclosporine, both of which are taken orally in the form of soft capsules. The study will last for a period of 24 weeks, during which the participants’ response to the treatment will be monitored. The main focus will be on the difference in improvement between the two groups from the start of the study to the end of the 24 weeks. Additionally, the study will assess changes in the severity of hand eczema, quality of life, and any side effects experienced by the participants.

Throughout the study, participants will have regular check-ups to evaluate their progress and any changes in their condition. The study aims to provide valuable information on which medication might be more effective for treating hand eczema, potentially leading to better treatment options for patients in the future.

]]> Study on Abrocitinib for Patients with Moderate to Severe Chronic Hand Eczema Unresponsive to Corticosteroids https://clinicaltrials.eu/trial/study-on-abrocitinib-for-patients-with-moderate-to-severe-chronic-hand-eczema-unresponsive-to-corticosteroids/ Wed, 29 Apr 2026 14:28:37 +0000 https://clinicaltrials.eu/trial/study-on-abrocitinib-for-patients-with-moderate-to-severe-chronic-hand-eczema-unresponsive-to-corticosteroids/ This clinical trial is focused on studying chronic hand eczema, a skin condition that causes redness, itching, and sometimes blisters on the hands. The trial will evaluate a treatment called abrocitinib, which is a type of medication known as a Janus kinase (JAK)1 inhibitor. This medication is being tested to see if it can help people with moderate to severe chronic hand eczema that has not improved with corticosteroid therapy, a common treatment for this condition.

The purpose of the study is to assess the effectiveness, safety, and tolerability of abrocitinib in treating chronic hand eczema. Participants in the study will be randomly assigned to receive either the medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for a period of 32 weeks, during which participants will take the medication or placebo orally in the form of film-coated tablets. Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms.

This trial aims to provide valuable information on whether abrocitinib can be an effective treatment option for those suffering from chronic hand eczema. By participating, individuals will contribute to research that could lead to better management of this challenging skin condition.

]]> Study on the Effectiveness and Safety of Ruxolitinib Cream for Adults with Chronic Hand Eczema https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ruxolitinib-cream-for-adults-with-chronic-hand-eczema/ Wed, 29 Apr 2026 14:26:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ruxolitinib-cream-for-adults-with-chronic-hand-eczema/ This clinical trial is focused on studying Chronic Hand Eczema, a condition where the skin on the hands becomes inflamed, itchy, and sometimes painful over a long period. The study is testing a treatment called Ruxolitinib cream, which is applied to the skin. This cream is being compared to a Vehicle Cream, which looks and feels the same but does not contain the active ingredient.

The purpose of the study is to evaluate how effective and safe Ruxolitinib cream is for treating adults with moderate to severe Chronic Hand Eczema. Participants in the study will be randomly assigned to use either the Ruxolitinib cream or the Vehicle Cream for a period of 16 weeks. During this time, neither the participants nor the researchers will know which cream is being used, a process known as “double-blind.” After this period, all participants will have the opportunity to use the Ruxolitinib cream in an open-label extension, meaning everyone will know they are using the active treatment.

The study will monitor participants’ skin condition and any changes in symptoms such as itching and pain. The goal is to see if the Ruxolitinib cream can improve the symptoms of Chronic Hand Eczema more effectively than the Vehicle Cream. Participants will be regularly assessed to track their progress and any side effects they might experience. This trial aims to provide valuable information on the potential benefits of Ruxolitinib cream for people suffering from this persistent skin condition.

]]> Study on the Effectiveness and Safety of Deucravacitinib for Adults with Chronic Hand Eczema https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-deucravacitinib-for-adults-with-chronic-hand-eczema/ Wed, 29 Apr 2026 14:26:13 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-deucravacitinib-for-adults-with-chronic-hand-eczema/ This clinical trial is focused on studying Chronic Hand Eczema, a condition where the skin on the hands becomes red, itchy, and inflamed over a long period. The study will test the effectiveness and safety of a medication called Deucravacitinib, which is taken as a 6 mg film-coated tablet. Participants in the study will either receive this medication or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how well Deucravacitinib works in treating adults with chronic hand eczema. Participants will take the medication or placebo daily for up to 16 weeks. Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms. The study will also assess the impact of the treatment on participants’ quality of life and the severity of their eczema.

During the study, various assessments will be conducted, including self-assessments by participants and evaluations by healthcare professionals. These assessments will help determine the effectiveness of the treatment in reducing the symptoms of chronic hand eczema. The study will also monitor the safety of the medication by checking for any side effects and changes in skin health. The trial aims to provide valuable information on the potential benefits of Deucravacitinib for individuals suffering from this persistent skin condition.

]]> Study on Oral Roflumilast for Treating Chronic Hand Eczema in Adults https://clinicaltrials.eu/trial/study-on-oral-roflumilast-for-treating-chronic-hand-eczema-in-adults/ Wed, 29 Apr 2026 14:24:42 +0000 https://clinicaltrials.eu/trial/study-on-oral-roflumilast-for-treating-chronic-hand-eczema-in-adults/ This clinical trial is focused on studying the treatment of chronic hand eczema, a persistent skin condition that causes redness, itching, and inflammation on the hands. The study will use a medication called Roflumilast, which is taken as a film-coated tablet. Roflumilast is a type of medicine known as a PDE4-inhibitor, which works by reducing inflammation in the body. Some participants in the study will receive a placebo, which looks like the real medication but does not contain any active ingredients.

The purpose of the study is to investigate how effective and safe Roflumilast is for adults with chronic hand eczema. Participants will take the medication or placebo orally for a period of up to 28 days. Throughout the study, researchers will monitor the severity of the eczema and any changes in the participants’ quality of life. The study will also track any side effects or adverse reactions to the treatment.

Participants will be assessed on various aspects, such as the reduction in eczema severity and improvements in their daily life activities. The study aims to see if Roflumilast can significantly reduce the symptoms of chronic hand eczema and improve the overall well-being of those affected by this condition. The trial is expected to continue until 2028, with the recruitment of participants having started in August 2023.

]]>